Term
| MOA inhibits synthesis of mycolic acid by inhibiting enzymes. Complex w/NADH which inhibits the oxygen dependent pathway |
|
Definition
|
|
Term
| 1st line for M. tub and is a bacerialstatic |
|
Definition
|
|
Term
| Hepatotoxic and neurotoxic |
|
Definition
|
|
Term
| Requires acetylaters to work and is water soluble |
|
Definition
|
|
Term
| Blocks RNA synthesis by binding to DNA dependent RNA polymerase |
|
Definition
|
|
Term
| 1st line for M. tub and is bactericidal |
|
Definition
|
|
Term
| Adverse rxns include Hepatitis in elderly and alcoholics, GI problems, and proteinuria |
|
Definition
|
|
Term
| Turns body fluids and shat red/orange |
|
Definition
|
|
Term
| Resistance by pt mutations on proB gene of beta subunit |
|
Definition
|
|
Term
| Similar to Rifampin with longer half life |
|
Definition
|
|
Term
| Given to patients who are intolerant or resistant to Rifampin. Good for MAI or atypical Myco |
|
Definition
|
|
Term
| MOA blocks arabio-galactin component of myco cell wall |
|
Definition
|
|
Term
| 1st line for M. tub in combination/ bacteriostatic |
|
Definition
|
|
Term
| Sides include visual disturbance and retinal damage |
|
Definition
|
|
Term
| Similar MAO as Isoniazid/ only used for M. tub in short term situations |
|
Definition
|
|
Term
| An M. tub enzyme converts this drug to active form |
|
Definition
|
|
Term
| Cannot be used along with a protease inhibitors for HIV |
|
Definition
|
|
Term
| Inhibits bacterial folic acid synthesis |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Sides include Hemolysis dude to G-6-DPH, GI, rash |
|
Definition
|
|
Term
| MAO is directly binding to DNA |
|
Definition
|
|
Term
| Alternative to M. leprosy and causes skin discoloration |
|
Definition
|
|
Term
| MAO forming pores or channels by interacting with ergosterol allowing ion leakage |
|
Definition
|
|
Term
| Nephrotoxicity, lipid formulations bind to mammalian membranes much less readily. Therefore, they reduce drug induced renal impairments |
|
Definition
|
|
Term
| For systemic fungal infections, meningitis, blader |
|
Definition
|
|
Term
| MAO 5-FU inhibits thymidylate synthase, human cells don't react |
|
Definition
|
|
Term
| Reversible bone marrow suppression and bacteria flora toxicity are sides |
|
Definition
|
|
Term
| Bacteria become resistant at low doses |
|
Definition
|
|
Term
| A base analogue but does not treat cancer |
|
Definition
|
|
Term
| Ergosterol inhibits 14-alpha-methylsterols, disrupting phospholipid packaging |
|
Definition
|
|
Term
| Sides include steroid problems and Hepatotoxic |
|
Definition
|
|
Term
| Used as a topical cream for orapharyngeal and cutaneous fungal infections |
|
Definition
|
|
Term
| Topical and Parental route with Sides of burning, skin problems, and itching used for fungal infections |
|
Definition
|
|
Term
| Broad Spectrum Fungal fighter, suppressive therapy of histoplasmosis in HIV. Well used in AIDS patients. Crosses BBB during inflammation. |
|
Definition
|
|
Term
| Increase plasma of phenytoin, zidovudine, cyclosporine, and warfarin |
|
Definition
|
|
Term
| Crosses BBB with out inflammation and resistant to 1st pass metabolism |
|
Definition
|
|
Term
| Increases Terfonadine, and can inhibit the conservation of other drugs |
|
Definition
|
|
Term
| Sides include loss of libido, gynecomastia, and hepatitis |
|
Definition
|
|
Term
| Not recommended in pregnant and nursing |
|
Definition
|
|
Term
| Losses absorption when introduced to increased pH in the stomach or H2 inhibitor |
|
Definition
|
|
Term
| Same Mechanism as Amphotericin B and looks like it. Treats candida of GI, mucosa, topical, skin, and vagina |
|
Definition
|
|
Term
| Systemic skin, hair, and nails infected with microsporum, ipidermophytes, trichophytons |
|
Definition
|
|
Term
| Inhibit enzyme gulcan synthase, required for fungal cell wall component b 1-3 D glucagon |
|
Definition
|
|
Term
| Used for candidas esophageal and abdominal. Prophylaxis for Candida infections of hematopoietic stem cell transplantation |
|
Definition
|
|
Term
| Mucosal and invasive candida, aspergillosis, and pneumocystis carinii. Acceptible safety profile |
|
Definition
|
|
Term
| Inhibitis fungal squalene monoozygenase |
|
Definition
|
|
Term
| Used for Tinea capitis, aspergillosis, onychomycosis (ring worms). 1% cream |
|
Definition
|
|
Term
| The main part of Mycobacterium cell wall, making them acid fast |
|
Definition
|
|
Term
| What two drugs make multi drug resistant TB |
|
Definition
|
|
Term
| XDR TB is resistant to Isoniazid and rifampin and also |
|
Definition
| Any fluoroquinolone and at least one of the following (amikacin, kanamycin, or capreomycin) |
|
|
Term
|
Definition
| No drugs currently available to treat strains |
|
|
Term
| If someone is diagnosed with TB patients are watched while taking medicine |
|
Definition
| Direct Observation Therapy |
|
|
Term
| Best drug therapy for M. tub |
|
Definition
| 6 months of one drug is better then two years of 4 drugs |
|
|
Term
| 20% of people may develop anti-DNA antibodies(lupus-like) while taking this |
|
Definition
|
|
Term
| When TB forms grunulomas, especially caseous granulomas they can form: |
|
Definition
|
|
Term
| Always used parenterally, very toxic, is a 1st line M. tub drug in other countries |
|
Definition
|
|
Term
| When you use this drug for something like HIV with low CD4 counts for pneumocystosis jirovecii instead of for m. leprae its called |
|
Definition
|
|
Term
| Two drugs which are affective against Atypical Myco |
|
Definition
|
|
Term
| Cannot be given parenterally due to renal toxicity which distinguishes it from another similar drug |
|
Definition
|
|
Term
| Inhibits fungal micro spindle (mitosis at metaphase) |
|
Definition
|
|
